Advertisement

Topics

Latest "MissionCelogos is a biotechnology company" News Stories

03:58 EDT 26th April 2018 | BioPortfolio

Here are the most relevant search results for "MissionCelogos is a biotechnology company" found in our extensive news archives from over 250 global news sources.

More Information about MissionCelogos is a biotechnology company on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about MissionCelogos is a biotechnology company for you to read. Along with our medical data and news we also list MissionCelogos is a biotechnology company Clinical Trials, which are updated daily. BioPortfolio also has a large database of MissionCelogos is a biotechnology company Companies for you to search.

Showing "MissionCelogos biotechnology company" News Articles 1–25 of 22,000+

Thursday 26th April 2018

Edge Therapeutics Inc EDGE Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09032018] Prices from USD $250

SummaryEdge Therapeutics Inc Edge Therapeutics is a clinicalstage biotechnology company that discovers, develops and commercializes a range of hospitalbased therapies. The company offers hospital based therapies capable of transforming treatment paradigms in the management of lifethreatening, acute neurological conditions. Its lead pipeline products include EG1962, a proprietary formulation, which...


Bone Therapeutics SA : Strengthens Board with the Appointment of Claudia D'Augusta as Non-Executive Director

Press release Bone Therapeutics Strengthens Board with the Appointment of Claudia D'Augusta as Non-Executive Director Claudia D'Augusta brings significant financial and capital markets experience Gosselies, Belgium, 26 April 2018, 7am CEST - BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical ...

Vistin Pharma ASA : Delivers 22% revenue growth in first quarter 2018

  Oslo, Norway, 26 April 2018   Vistin Pharma ASA delivers a revenue growth of 22 percent from NOK 43.4 million in the first quarter 2017 to NOK 52.8 million in the first quarter 2018. The underlying demand for metformin is still strong and Vistin Pharma sales of metformin as active pharmaceutical ingredients were nine percent higher compared to first quarter 2017. EBITDA from c...


Biocartis Group NV: BIOCARTIS Q1 2018 BUSINESS UPDATE

PRESS RELEASE: REGULATED INFORMATION  Thursday, 26 April 2018, 07:00 CEST BIOCARTIS Q1 2018 BUSINESS UPDATE   Mechelen, Belgium, 26 April 2018 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today provides a business update for the first quarter of 2018 and an outlook for the remain...

MDxHealth Announces Positive Clinical Updates for ConfirmMDx

NEWS RELEASE                                                                                         REGULATED INFORMATION                                                                                       ...

Zealand announces successful End-of-Phase 2 meeting with FDA on glepaglutide for short bowel syndrome

Company announcement - No. 12/2018 Zealand announces successful End-of-Phase 2 meeting with FDA on glepaglutide for short bowel syndrome Glepaglutide is in development as a new treatment option for patients with short bowel syndrome The pivotal phase 3 trial is on track for initiation in Q3 2018 Copenhagen, Denmark, April 26, 2018 - Zealand Pharma (Zealand) today announced...

Eli Lilly and Company Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 16022018] Prices from USD $350

Eli Lilly and Company Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Eli Lilly and Company Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken b...

Wednesday 25th April 2018

20152023 World Coronary Artery Disease Therapeutics Market Research Report by Product Type, EndUser / Application and Regions / Countries [Report Updated: 23022018] Prices from USD $2800

SummaryThis report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions.Market Segment as follows:By Region / Countries North America U.S., Canada, Mexico Europe Germany, U.K., France, Italy, Russia, Spain etc South Americ...

EYPT Up 98% This Month, USNA In Good Health, MDXG To Report Q1 Results

EyePoint Pharmaceuticals gained 19.10% on Wednesday. The Company's NDA for YUTIQ micro-insert, proposed for treatment of non-infectious posterior segment uveitis, is under FDA review - with a decision expected on November 5, 2018.

Sutherland Asset Management Corporation Announces Pricing of Public Offering of Notes

The offering is expected to close on April 27, 2018and is subject to customary closing conditions. The Company has applied to list the Notes Read more...

Galapagos reports first quarter 2018 results

Key Q1 2018 results: Group revenues of €44.8 million Operating loss €32.0 million Net loss of €37.3 million End of first quarter cash and cash equivalents €1.1 billion Clinical progress reported in CF and OA, preparations for multiple late stage studies Webcast presentation tomorrow, 26 April 2018, at 14.00 CET/8 AM ET, +32 2 404 0659, code 5747918, www.glp

Incyte Highlights Abstracts Accepted for Presentation at the 2018 ASCO Annual Meeting

Incyte Corporation (Nasdaq:INCY) announces that multiple abstracts from its research and development portfolio will be presented at the upcoming 2018 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois from June 1-5, 2018. Data at ASCO 2018 include oral presentations from a Phase 1 study of ruxolitinib (Jakafi®), lena...

Catabasis Pharmaceuticals Presents New Edasalonexent Data Showing Significantly Slowed Duchenne Muscular Dystrophy Disease Progression as Measured by MRI Through One Year of Treatment

-- Statistically Significant Improvements in MRI T2 Rate of Change Compared to Control Consistent with Improvements Demonstrated in Assessments of Muscle Function in MoveDMD® Trial -- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage

Pomerantz LLP: SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Myriad Genetics, Inc. of Class Action Lawsuit and Upcoming Deadline - MYGN

NEW YORK, NY / ACCESSWIRE / April 25, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against Myriad Genetics, Inc. ("Myriad" or the "Company") (NASDAQ: MYGN) and certain ...

Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Wednesday, May 9, 2018 following release of its first quarter 2018 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least ten minut...

Robert A. Essner, former Chairman and Chief Executive of Wyeth, named Executive Chairman of ...

NEW YORK, NY--(Marketwired - April 25, 2018) -ELUCIDA ONCOLOGY, INC ®, a biotechnology company focused on developing and commercializing a first-in-class, ultra-small Read more...

Pivotal SAKURA Phase 3 Clinical Data to be Featured in Oral and Poster Presentations at The Aesthetic Meeting 2018

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced oral and ePoster presentations of clinical data from the company’s two pivotal SAKURA Phase 3 trials of DaxibotulinumtoxinA Injectable (RT002) at The Aesthetic Meeting 2018, organized by th...

CONMED Corporation Announces First Quarter 2018 Financial Results

CONMED Corporation (Nasdaq: CNMD) today announced financial results for the first quarter ended March 31, 2018. First Quarter 2018 Highlights Sales of $202.1 million increased 8.3% year over year as reported and 6.8% in constant currency and as adjusted(1). Domestic revenue increased 6.9% year over year as report...

Aurinia to Present at the Bloom Burton & Co. Healthcare Investor Conference on May 3, 2018

Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced that Celia Economides, Vice President, Corporate and Public Affairs, will present at the Bloom Burton & Co. Healthcare Investor Conference on Thursday, May 3rd at 1:30pm EDT. A webcast will be available and can be accessed via the investor section of the Aurinia website, www.auriniapharma.co...

Deciphera Pharmaceuticals, Inc. to Report Clinical Data with DCC-2618 at the Upcoming 2018 American Society for Clinical Oncology (ASCO) Annual Meeting

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that an abstract highlighting DCC-2618, the Company’s KIT and PDGFRα inhibitor, has been selected for poster presentation and discussion at the 2018 American Society for Clinical Oncolog...

Los Angeles Investment Firm Named Small Business Investment Company of the Year

Jeri J. Harman Managing Partner and CEO Avante Mezzanine Partners SBIC, LP Los Angeles, California  Avante Mezzanine Partners SBIC, LP is led by Managing Read more...

Syntimmune Appoints Andrew Cheng, M.D., Ph.D., to Board of Directors, Bolstering Clinical Development Expertise

Syntimmune, Inc., a clinical-stage biotechnology company developing antibody therapeutics targeting FcRn, today announced an expansion of its board of directors with the appointment of Andrew Cheng, M.D., Ph.D., the chief medical officer and an executive vice president at Gilead Sciences (NYSE: GILD). Dr. Cheng has a 20-year track record of...

Flex Pharma to Report First Quarter 2018 Financial Results on May 2, 2018

Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with severe neurological diseases such as multiple sclerosis (MS), Charcot-Marie-Tooth (CMT) and amyotrophic lateral sclerosis (ALS) under FDA Fast Track designation, announced today that ...

Herbalife Nutrition Welcomes New Members to its Board of Directors

Herbalife Nutrition (NYSE:HLF), announced today the election of four new members to its Board of Directors. The newly elected directors, Nicholas Graziano, Alan LeFevre, Juan Miguel Mendoza, and Margarita Palau-Hernandez, will join their fellow directors in helping the Company deliver on its purpose of making the world healthier and happier. Stepp...

Five Prime to Present at 2018 ASCO Annual Meeting

Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced that it will present two posters during the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 1-5, 2018, in Chicago.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks